Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer
Disease area: Thoracic oncology

Abstract

IntroductionAlternative splicing is an important component of tumorigenesis. Recent advent of exon array technology enables the detection of alternative splicing at a genome-wide scale. Few analysis tools of high-throughput alternative splicing are currently available. We propose a novel statistical approach for the detection of splicing changes in exon array data. Using this methodology, we investigated the genome-wide alteration of alternative splicing in NSCLC patients treated by bevacizumab/erlotinib.MethodsWe used restricted constrained correspondence analysis (RCCA) to explore the exonic variations with respect to disease phenotypes. We applied RCCA on oncological data investigating the response to targeted therapy on late stage non-squamous NSCLC. Exonic expression levels were measured on bronchospic biopsies from 42 patients treated by bevacizumab/erlotinib using Affymetrix GeneChip Human Exon 1.0 ST Array. Patients were categorized into responders/non-responders according to their response to treatment.ResultsSplicing candidates reveal a series of genes related to carcinogenesis, cell adhesion, tumor aggressiveness, apoptosis, proliferation and differentiation, as well as tumor growth or tumor suppression, with indication of known alternative splicing in a majority of genes. Diagnostic markers of metastasis and micrometastasis were also found.ConclusionRCCA facilitates the identification of biologically relevant alternative splicing events in high-throughput exon array data. The flexibility of this approach makes it ideal as a screening procedure for identification of splicing sites candidates and group-specific alternative splicing events.

Rating:

Share or cite this content

Citations should be made in the following way:
F. Baty, M. Brutsche (St. Gallen, Switzerland). High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib. Eur Respir J 2014; 44: Suppl. 58, 402

Member's Comments

No comment yet.

Related content which might interest you: Telomere-associated gene network in lung adenocarcinoma Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey Year: 2015 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Surface expression of CTLA-4 on CD4/CD25high cells in lung cancer Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Surface vs. intracellular CTLA-4 expression in lung cancer Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Exploring the 24h-effect of targeted therapies in non-small cell lung cancer from exon array blood profiling using dually constrained correspondence analysis Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Methylation associated pathway activity deregulation in lung adenocarcinoma Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer Year: 2014 The methylation profiling of multiple tumor suppressor genes in plasma cell-free DNA from patients with NSCLC versus non-malignant tumors - pilot study Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Development of an invasive 3D lung tumor model for oncological research Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Metabolic modification as a potential therapeutics approach in lung cancer Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Molecular profiling of lung squamous carcinogenesis Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP) Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy Year: 2013 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Optimization of cfDNA routine use for NSCLC genomic alteration analysis Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease Year: 2016 Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015